Hypoglycemia Seriousness and Weight Gain as Determinants of Cardiovascular Disease Outcomes Among Sulfonylurea Users

Date: 
May, 2017

May 12, 2017. This cohort study quantified the association between cardiovascular disease (CVD) outcomes with hypoglycemia and weight gain in patients with type 2 diabetes treated with sulfonylureas. Patients were identified from a national electronic health database (dates: January 2009 to December 2014). Hypoglycemic events were identified and characterized as serious or nonserious. Regression analysis was used to assess the association between hypoglycemia frequency and weight change magnitude and incidence of acute myocardial infarction (AMI), congestive heart failure (CHF), and stroke. A total of 143,635 patients were included: 5,669 cases of AMI, 14,109 incident cases of CHF, and 7,017 strokes were observed. The association between overall hypoglycemia and each CVD outcome was positive, with stronger associations for serious hypoglycemia. Weight change showed a U-shaped relationship: relative to weight stability, risk increased with both weight loss and weight gain.